My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

DexCom Inc. (DXCM) — RQD Stock Rating Cockpit

$80.19 -2.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $79.98

DexCom Inc. (DXCM) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (60.1% gross margin, 22% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $29.91B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DXCM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DXCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, DexCom Inc. (NASDAQ: DXCM) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $80.19 (-2.82% 1D, market cap $29.91B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, DXCM ranks #20 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DXCM compare to WST and RMD in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), DXCM carries a Roarable B (75/100 RQD), trailing P/E of 36.1x, gross margin of 60.1%, and ROIC of 21.6%. By comparison, WST (West Pharmaceutical Services Inc.) holds a B+ grade (76/100 RQD, P/E 59.4x, ROIC 17.9%, cap $27.63B) and RMD (ResMed Inc.) posts a A- grade (81/100 RQD, P/E 25.4x, ROIC 22.9%, cap $33.32B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DXCM?
▼

Per DXCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001093557), DexCom Inc. generated $4.66B in revenue (+15.6% YoY), $836.3M in net income, and $1.08B in free cash flow against $6.34B in total assets and $1.62B in total debt. Key quantitative strengths: Strong cash generator (60.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 DXCM TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $DXCM, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $DXCM R/R 3.6 : 1 • RQD 75/100 (B)
$DXCM
Spot $80.19
1. GET IN (ENTRY)
$79.71–$80.59
2. HARD STOP (SUP)
$76.90 (-4.1%)
3. GET OUT (T1/T2)
$87.25 / $92.06
STOP-LOSS FLOOR (SUP $76.90): Hard stop sits 4.1% below spot to cap downside below key institutional support. If $DXCM closes a daily candle below $76.90, step aside.
PROFIT TARGETS (RES $87.25 / $92.06): Scale out 50% at T1 (+8.8%) and trail stop to breakeven for T2 (+14.8%).
Want this $DXCM sheet + Today's Top 3 Trades emailed free? Paper Trade $DXCM →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $DXCM Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $79.97 (-0.27%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 23.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510075
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk B
Cash (19)Whales (10)SEC (18)Macro (12)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+7.6% Base Target
$102 Bull$86 Base$66 Bear
📬 FREE DXCM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DXCM)Realized 20D OHLCV Swing Band: ±5.2%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY DXCM SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 23.1% FCF Margin ($1.08B FCF) & 60.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 7.14 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
83
Grade A$84.63-5.6% Next Q
Q2 (-2Q)
80
Grade A-$79.92+4.3% Next Q
Q3 (-1Q)
78
Grade A-$83.33-3.8% Next Q
Current
75
Grade B$80.19+7.4% Hist 90D α
Trajectory: A (83) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DXCM Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, DXCM faces multiple-compression risk if 36.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 57.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($83.30) or 200D SMA ($75.63) invalidates the momentum regime and cuts Target Base ($86.32) toward Bear Floor ($65.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DXCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DXCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
44.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
7.14>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE65% OF RANGE
L: $57$80.19H: $93
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (60.1% gross margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on DXCM

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (95)

21.6% ROIC with 60.1% gross margin and 3.57% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 7.14 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (63)

26/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like DXCM
  • ✓Strong cash generator (60.1% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (DXCM Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DXCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.36%▼ DESCENDING CHANNEL
2026-11-22O $82.52H $82.52L $80.19C $80.19VOL 4.47M
$94.62$86.21$77.81$69.41$61.00RES $87.51SUP $72.19$80.192026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 21.6% vs WACC 7.5%)

DXCM Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $96.72 vs Spot $80.19
SIGNIFICANTLY UNDERVALUED (+17.1%)
Undervalued Zone (< $82) Fair Value Corridor ($82–$111) Overvalued (> $111)
$80
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own DXCM Growth & WACC Assumptions

YOUR DCF TARGET
$148.35
5-Yr Annual FCF Growth Rate: 21.7%
Discount Rate (WACC Hurdle): 7.5%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +17.1% vs $80.19 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
27.8%/yr Implied 5Y Growth

vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
LLY → DXCM Analyst Hypothesis
Real-world payer claims data show clinicians co-prescribe Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs) alongside GLP-1 initiation for metabolic feedback, offsetting delayed progression to basal insulin.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DXCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DXCM)

Health Care Rank #20 of 1015 ⚔️ WST vs DXCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DXCM vs. WST, RMD, MDLN, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, DexCom Inc. (DXCM) ranks #20 by composite RQD confidence (75/100, grade B) and #58 by equity capitalization ($29.91B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 81/100 (A-) compared with DXCM at 75/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DXCM ACTIVE
DexCom Inc.
B 75/100 36.1x 60.1% 21.6% -2.82% $29.91B Benchmark Subject
WST
West Pharmaceutical Services Inc.
B+ 76/100 59.4x 35.9% 17.9% -1.83% $27.63B /wst-vs-dxcm →
RMD
ResMed Inc.
A- 81/100 25.4x 59.4% 22.9% -2.35% $33.32B /rmd-vs-dxcm →
MDLN
Medline Inc.
D 48/100 — — 8.2% -3.37% $49.77B /mdln-vs-dxcm →
BDX
Becton Dickinson and Company
C+ 67/100 32.2x 45.4% 4.9% -1.55% $57.95B /bdx-vs-dxcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001093557 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DexCom Inc. (DXCM) reported GAAP revenue of $4.66B (+15.6% vs. FY2024 revenue of $4.03B , and +28.7% cumulative change since FY2023) , GAAP net income of $836.3M, operating cash flow of $1.44B, and free cash flow of $1.08B (+70.8% YoY). On the balance sheet, DXCM closed FY2025 with $6.34B in total assets against $1.62B in total debt (Altman Z-Score: 7.14, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.66B $836.3M $1.44B $1.08B $6.34B $1.62B
FY2024 (FY) 2024-12-31 $4.03B $576.2M $989.5M $630.7M $6.48B $1.97B
FY2023 (FY) 2023-12-31 $3.62B $541.5M $748.5M $585.5M $16.59B $3.88B

3. DXCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DXCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, DexCom Inc. (NASDAQ: DXCM) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $80.19 (-2.82% 1D, market cap $29.91B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, DXCM ranks #20 in composite RQD confidence.

How does DXCM compare to WST and RMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DXCM carries a Roarable B (75/100 RQD), trailing P/E of 36.1x, gross margin of 60.1%, and ROIC of 21.6%. By comparison, WST (West Pharmaceutical Services Inc.) holds a B+ grade (76/100 RQD, P/E 59.4x, ROIC 17.9%, cap $27.63B) and RMD (ResMed Inc.) posts a A- grade (81/100 RQD, P/E 25.4x, ROIC 22.9%, cap $33.32B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DXCM?

Per DXCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001093557), DexCom Inc. generated $4.66B in revenue (+15.6% YoY), $836.3M in net income, and $1.08B in free cash flow against $6.34B in total assets and $1.62B in total debt. Key quantitative strengths: Strong cash generator (60.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DXCM trading relative to its 50-day, 200-day, and 52-week technical levels?

DXCM last traded at $80.19 (-2.82% on volume of 4,466,482 shares), positioning the stock -3.73% below its 50-day simple moving average ($83.30) and +6.03% above its 200-day simple moving average ($75.63). Across its 52-week range of $56.72 to $92.59, DXCM sits at the 65.4% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.2% ($76.02 to $84.36).

ROARABLE RATING BRIEF • RQD 75/100 (B) ✓ SEC XBRL & RQD VERIFIED

DXCM — DexCom Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

DexCom Inc. (DXCM) earns a live Roarable RQD composite score of 75/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $80.19 (-2.82% 1D, market capitalization $29.91B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 21.6%, gross margin of 60.1%, operating margin of 19.6%, and free cash flow yield of 3.57%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (18/20): Incorporates a 1.10x equity beta, Altman Z-Score of 7.14, Piotroski F-Score of 9/9, and Debt/Equity of 0.55x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. The company's products include Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs). Per the same graph, the customer base includes clinicians and payers, with reimbursement channels including durable medical equipment (DME) and pharmacy benefit managers (PBMs).

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), DexCom Inc. (DXCM) reported $4.66B in annual revenue (up from $4.03B in FY2024, +15.6% YoY) and $836.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.62B revenue, $541.5M net income) through FY2025, DXCM scaled operating cash flow to $1.44B and free cash flow to $1.08B, backed by $6.34B in total assets against $1.62B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 75/100): Strong cash generator (60.1% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $56.72 – $92.59 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 36.1x trailing P/E and 25.2x EV/EBITDA against 19.6% operating margins and a 1.10x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain field is NONE, so no formal upstream/downstream supplier map is available in source data. The only documented linkage is the GLP-1 companion-prescription dynamic with Eli Lilly (LLY), which the graph classifies as an analyst hypothesis rather than a confirmed relationship. The mechanism: GLP-1 initiation may be accompanied by CGM use for metabolic feedback, offsetting delayed progression to basal insulin. The graph identifies a second-order constraint: DME channel restructuring and lower ASP on OTC biosensors may dilute revenue per user even as unit volumes grow. Investors should watch unit growth versus per-unit pricing, and whether payer coverage expands beyond insulin-treated diabetics.

  • Key Question #1: Can DXCM sustain or expand its 19.6% operating margin and 21.6% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.66B and free cash flow of $1.08B, how will capital allocation balance growth reinvestment against $1.62B in total debt?
  • Key Question #3: How sensitive is DXCM's 30.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.10x)?

DXCM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DexCom Inc. (DXCM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DXCM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DXCM Bull vs. Bear Conversation Board — What's Your Call at $80.19?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DXCM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DXCM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $95.46 (+16.0%)
📌 Pinned Debate

Per the RQD rating, a 21.6% ROIC and 9/9 Piotroski F-Score point to strong cash economics and balance-sheet quality.

Picked up a starter position in DXCM in my $100K Virtual Cash book at $82.29. Per the RQD rating, a 21.6% ROIC and 9/9 Piotroski F-Score point to strong cash economics and balance-sheet quality.. Trading inside a $54.11–$92.59 52-week range with 3.57% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 13/20 institutional whale-flow stock at $82.29 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $65.83 (-20.0%)
Spot @ $82.29

At a 36.1 P/E (TTM) and 3.57% FCF yield, the valuation prices in substantial growth with limited cash-based margin of safety.

Careful chasing DXCM at $82.29. At a 36.1 P/E (TTM) and 3.57% FCF yield, the valuation prices in substantial growth with limited cash-based margin of safety.. Gross margin is 60.1%, but operating margin is 19.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $65.83 on multiple compression.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE